Sammenlign metoder
Gennemgå dine valgte metoder side om side; rækker, der afviger, er fremhævet.
| POEM (Patient-Oriented Eczema Measure)× | EASI (Eczema Area and Severity Index)× | |
|---|---|---|
| Fagområde | Dermatologi | Dermatologi |
| Familie | Process / pipeline | Process / pipeline |
| Oprindelsesår≠ | 2004 | 2001 |
| Ophavsperson≠ | Charman CR, Venn AJ, Williams HC | Hanifin JM, Thurston M |
| Type≠ | Self-report | Clinician-rated |
| Oprindelig kilde≠ | Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519. DOI ↗ | Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18. DOI ↗ |
| Aliasser | POEM Score | EASI Index |
| Relaterede | 2 | 2 |
| Resumé≠ | The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care. | The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA). |
| ScholarGateDatasæt ↗ |
|
|